Kisqali in Combination with Hormonal Therapy and Ovarian Suppression Effective Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Disease in Premenopausal Women: 2017 SABCS

7:25
 
Share
 

Manage episode 193047358 series 1013829
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
The targeted therapy Kisqali (chemical name: ribociclib) is approved to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in postmenopausal women. Dr. Debu Tripathy, professor of medicine and chairperson of the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the results of the MONALEESA-7 study he presented at the 2017 San Antonio Breast Cancer Symposium showing that Kisqali can help treat premenopausal and perimenopausal women diagnosed with the same type of breast cancer.Listen to the podcast to hear Dr. Tripathy explain: why the study is important why ovarian suppression helps make the treatments more effective the side effects caused by Kisqali why he thinks this study will change practice Running time: 7:25

127 episodes available. A new episode about every 8 days averaging 15 mins duration .